Aminocaproic acid - instructions for use, dose, side effects, contraindications

The hemostatic agent inhibits the conversion of the fibrinolysin to the fibrinolysin, apparently due to inhibition of the activator of this process, and also has a direct inhibitory effect on fibrinolysin; inhibits the activating action of streptokinase, urokinase and tissue kinases on fibrinolysis, neutralizes the effects of kallikrein, trypsin and hyaluronidase, reduces the permeability of capillaries. Has anti-allergic activity, improves the antitoxic function of the liver.

Pharmacokinetics:When administered intravenously, the effect is manifested through 15-20 minutes. It is excreted by the kidneys - 40-60% of the administered amount through 4 hour is excreted in the urine unchanged.

Indications:

Bleeding (hyperfibrinolysis, hypo- and afibrinogenemia), bleeding during surgical interventions and pathological conditions, accompanied by increased fibrinolytic activity of the blood (with neurosurgical, intracavitary, thoracic, gynecological and urological operations, incl.on the prostate gland, lungs, pancreas; tonsillectomy, after dental interventions, in operations using the device of artificial circulation).

Diseases of internal organs with hemorrhagic syndrome; premature detachment of the placenta, complicated abortion.

Prevention of secondary hypofibrinogenemia in massive transfusions of canned blood.

Contraindications:

Hypersensitivity, hypercoagulation (thrombosis, thromboembolism), propensity to thrombosis and thromboembolic diseases, cerebral circulation disorders, disseminated intravascular coagulation, pregnancy. With renal failure, the use is contraindicated.

Carefully:

Arterial hypotension, valvular heart disease, hematuria, bleeding from the upper urinary tract unidentified etiology, liver failure, chronic renal failure.

Pregnancy and lactation:

Contraindicated use of the drug during pregnancy.

The use of the drug during lactation (breastfeeding) is possible only in cases where the intended use for the mother exceeds the potential risk for the baby.

Dosing and Administration:

Amino-caproic acid is administered intravenously, drip.

If it is necessary to achieve a rapid effect (acute hypofibrinogenemia), intravenously drip to 100 ml of a sterile 5% solution on an isotonic solution of sodium chloride, at a rate of 50-60 drops per minute. During the first hour, a dose of 4-5 g is given, in case of continuing bleeding - until it stops completely - 1 g every hour for not more than 8 hours. If necessary, 5% solution of aminocaproic acid is repeated.

Children, at the rate of 100 mg / kg - in 1 hour, then 33 mg / kg / h; the maximum daily dose is 18 g / m2. The daily intake for adults is 5-30 g; for children under 1 year - 3 g; 2-6 years - 3-6 g; 7-10 years - 6-9 g. For acute blood loss: children under 1 year of age - 6 g, 2-4 years - 6-9 g, 5-8 years-9-12 g, 9-10 years - 18 g. Duration of treatment is 3-14 days.

Side effects:

Allergic reactions: increased individual sensitivity to the drug, which manifests itself with dizziness, nausea, diarrhea, skin rashes, tinnitus, nasal congestion, rhinitis (when these symptoms appear, you should reduce the dose or cancel the drug).

From the coagulation system of the blood: very rarely - subarachnoid and subcardial hemorrhages.

From the side of the cardiovascular system: with rapid intravenous administration possible - arterial hypotension, bradycardia, arrhythmia.

Other: very rarely - rhabdomyolysis, acute renal failure.

Overdose:

Symptoms: arterial hypotension, heart failure, renal insufficiency, in some cases - hypercoagulable with a risk of thrombosis and embolism.

Treatment: symptomatic therapy. For correction of increased blood coagulability is recommended to use streptokinase, urokinase, fibrinolysin and heparin.

Interaction:

Anticoagulants of direct and indirect action, antiaggregants decrease efficiency. You can combine with the introduction of hydrolysates, a solution of glucose (dextrose), anti-shock solutions. In acute fibrinolysis, fibrinogen should additionally be administered in an average daily dose of 2-4 g (maximum dose of 8 g). Decrease in efficacy with simultaneous reception of anticoagulants of direct and indirect action, antiplatelet agents.

Special instructions:

The purpose of the drug requires checking the fibrinolytic activity of blood and the concentration of fibrinogen in the blood. With intravenous administration, coagulogram monitoring is necessary, especially in coronary heart disease,after myocardial infarction, with pathological processes in the liver.

Form release / dosage:

Solution for infusions 5%.

Packaging:

For 100 ml in glass bottles for blood, transfusion and infusion preparations with a capacity of 100 ml. For 100 ml in polymer bottles with a capacity of 100 ml. 100 ml in polymer containers for single use infusion solutions, PVC containers, polyolefin containers.

Each polyvinyl chloride container is placed in a bag of polyethylene film.

For 1 bottle or container or a bag with a container with instruction for medical use put in a pack of cardboard box.

For 28 bottles with an equal number of instructions for medical use are placed in boxes of corrugated cardboard (for hospitals).

For 72 containers or a bag with containers with an equal number of instructions for medical use are placed in boxes of corrugated cardboard [for hospitals].

Storage conditions:In the dark place at a temperature of 0 to 20 ° C. Keep out of the reach of children. The preparation in glass bottles should be stored upright in a vertical position.

Shelf life:

3 years.Do not use after the expiration date indicated on the package.

Terms of leave from pharmacies:On prescription

Registration number:LS-000583

Date of registration:23.04.2010 / 18.04.2012

Expiration Date:Unlimited

The owner of the registration certificate:ESKOM NPK, OAO ESKOM NPK, OAO Russia

Manufacturer: & nbsp

ESKOM NPK, OAO Russia

Information update date: & nbsp07.08.2017

Illustrated instructions

Instructions

Aminocaproic acid (Aminocaproic acid)